Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tisotumab Vedotin in Chinese Subjects with Solid Tumors
NCT05866354Phase 1Completed
- Sponsor
- Zai Lab
- Start
- Jun 2023
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tisotumab vedotin in solid tumor, sponsored by Zai Lab. Primary endpoints: Area Under the Curve, Maximum Concentration and 3 more. Started Jun 2023; status: completed.
02
Drugs
tisotumab vedotin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05866354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05866354.